1 Market Overview

1.1 Product Overview and Scope of Targeted Drugs for Multiple Myeloma

1.2 Classification of Targeted Drugs for Multiple Myeloma by Type

1.2.1 Overview: Global Targeted Drugs for Multiple Myeloma Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type in 2021

1.2.3 Immunomodulator

1.2.4 Proteasome Inhibitors

1.2.5 Histone Deacetylase Inhibitors (HDACI)

1.2.6 Monoclonal Antibody

1.2.7 Other

1.3 Global Targeted Drugs for Multiple Myeloma Market by Application

1.3.1 Overview: Global Targeted Drugs for Multiple Myeloma Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospital

1.3.3 Drug Center

1.3.4 Clinic

1.3.5 Other

1.4 Global Targeted Drugs for Multiple Myeloma Market Size & Forecast

1.5 Global Targeted Drugs for Multiple Myeloma Market Size and Forecast by Region

1.5.1 Global Targeted Drugs for Multiple Myeloma Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Targeted Drugs for Multiple Myeloma Market Size by Region, (2017-2022)

1.5.3 North America Targeted Drugs for Multiple Myeloma Market Size and Prospect (2017-2028)

1.5.4 Europe Targeted Drugs for Multiple Myeloma Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size and Prospect (2017-2028)

1.5.6 South America Targeted Drugs for Multiple Myeloma Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Targeted Drugs for Multiple Myeloma Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Targeted Drugs for Multiple Myeloma Market Drivers

1.6.2 Targeted Drugs for Multiple Myeloma Market Restraints

1.6.3 Targeted Drugs for Multiple Myeloma Trends Analysis

2 Company Profiles

2.1 Celgene

2.1.1 Celgene Details

2.1.2 Celgene Major Business

2.1.3 Celgene Targeted Drugs for Multiple Myeloma Product and Solutions

2.1.4 Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Celgene Recent Developments and Future Plans

2.2 Exova

2.2.1 Exova Details

2.2.2 Exova Major Business

2.2.3 Exova Targeted Drugs for Multiple Myeloma Product and Solutions

2.2.4 Exova Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Exova Recent Developments and Future Plans

2.3 Natco Pharma

2.3.1 Natco Pharma Details

2.3.2 Natco Pharma Major Business

2.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Product and Solutions

2.3.4 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Natco Pharma Recent Developments and Future Plans

2.4 Intas Pharmaceuticals

2.4.1 Intas Pharmaceuticals Details

2.4.2 Intas Pharmaceuticals Major Business

2.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product and Solutions

2.4.4 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Intas Pharmaceuticals Recent Developments and Future Plans

2.5 Indiabulls Pharmaceutical

2.5.1 Indiabulls Pharmaceutical Details

2.5.2 Indiabulls Pharmaceutical Major Business

2.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product and Solutions

2.5.4 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Indiabulls Pharmaceutical Recent Developments and Future Plans

2.6 Cipla

2.6.1 Cipla Details

2.6.2 Cipla Major Business

2.6.3 Cipla Targeted Drugs for Multiple Myeloma Product and Solutions

2.6.4 Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Cipla Recent Developments and Future Plans

2.7 Glenmark Pharmaceuticals

2.7.1 Glenmark Pharmaceuticals Details

2.7.2 Glenmark Pharmaceuticals Major Business

2.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product and Solutions

2.7.4 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Glenmark Pharmaceuticals Recent Developments and Future Plans

2.8 Dr Reddy's Laboratories

2.8.1 Dr Reddy's Laboratories Details

2.8.2 Dr Reddy's Laboratories Major Business

2.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product and Solutions

2.8.4 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Dr Reddy's Laboratories Recent Developments and Future Plans

2.9 Qilu Pharmaceutical

2.9.1 Qilu Pharmaceutical Details

2.9.2 Qilu Pharmaceutical Major Business

2.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product and Solutions

2.9.4 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Qilu Pharmaceutical Recent Developments and Future Plans

2.10 Chia Tai-Tianqing

2.10.1 Chia Tai-Tianqing Details

2.10.2 Chia Tai-Tianqing Major Business

2.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product and Solutions

2.10.4 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Chia Tai-Tianqing Recent Developments and Future Plans

2.11 Hanson Pharm

2.11.1 Hanson Pharm Details

2.11.2 Hanson Pharm Major Business

2.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Product and Solutions

2.11.4 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Hanson Pharm Recent Developments and Future Plans

2.12 Meidakang Huakang Pharmaceutical

2.12.1 Meidakang Huakang Pharmaceutical Details

2.12.2 Meidakang Huakang Pharmaceutical Major Business

2.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product and Solutions

2.12.4 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Meidakang Huakang Pharmaceutical Recent Developments and Future Plans

2.13 Shandong Kongfu Pharmaceutical

2.13.1 Shandong Kongfu Pharmaceutical Details

2.13.2 Shandong Kongfu Pharmaceutical Major Business

2.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product and Solutions

2.13.4 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Shandong Kongfu Pharmaceutical Recent Developments and Future Plans

2.14 J&J

2.14.1 J&J Details

2.14.2 J&J Major Business

2.14.3 J&J Targeted Drugs for Multiple Myeloma Product and Solutions

2.14.4 J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 J&J Recent Developments and Future Plans

2.15 Takeda

2.15.1 Takeda Details

2.15.2 Takeda Major Business

2.15.3 Takeda Targeted Drugs for Multiple Myeloma Product and Solutions

2.15.4 Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Takeda Recent Developments and Future Plans

2.16 Amgen

2.16.1 Amgen Details

2.16.2 Amgen Major Business

2.16.3 Amgen Targeted Drugs for Multiple Myeloma Product and Solutions

2.16.4 Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Amgen Recent Developments and Future Plans

2.17 Bristol Myers Squibb

2.17.1 Bristol Myers Squibb Details

2.17.2 Bristol Myers Squibb Major Business

2.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product and Solutions

2.17.4 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 Bristol Myers Squibb Recent Developments and Future Plans

2.18 Abbvie

2.18.1 Abbvie Details

2.18.2 Abbvie Major Business

2.18.3 Abbvie Targeted Drugs for Multiple Myeloma Product and Solutions

2.18.4 Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.18.5 Abbvie Recent Developments and Future Plans

2.19 Seattle Genetics

2.19.1 Seattle Genetics Details

2.19.2 Seattle Genetics Major Business

2.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Product and Solutions

2.19.4 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.19.5 Seattle Genetics Recent Developments and Future Plans

2.20 Karyopharm Therapeutics

2.20.1 Karyopharm Therapeutics Details

2.20.2 Karyopharm Therapeutics Major Business

2.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product and Solutions

2.20.4 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.20.5 Karyopharm Therapeutics Recent Developments and Future Plans

2.21 PDL BioPharma

2.21.1 PDL BioPharma Details

2.21.2 PDL BioPharma Major Business

2.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Product and Solutions

2.21.4 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.21.5 PDL BioPharma Recent Developments and Future Plans

2.22 Roche

2.22.1 Roche Details

2.22.2 Roche Major Business

2.22.3 Roche Targeted Drugs for Multiple Myeloma Product and Solutions

2.22.4 Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.22.5 Roche Recent Developments and Future Plans

2.23 Sumitomo

2.23.1 Sumitomo Details

2.23.2 Sumitomo Major Business

2.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Product and Solutions

2.23.4 Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.23.5 Sumitomo Recent Developments and Future Plans

2.24 Merck

2.24.1 Merck Details

2.24.2 Merck Major Business

2.24.3 Merck Targeted Drugs for Multiple Myeloma Product and Solutions

2.24.4 Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.24.5 Merck Recent Developments and Future Plans

2.25 Biogen

2.25.1 Biogen Details

2.25.2 Biogen Major Business

2.25.3 Biogen Targeted Drugs for Multiple Myeloma Product and Solutions

2.25.4 Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.25.5 Biogen Recent Developments and Future Plans

2.26 Schering-Plough

2.26.1 Schering-Plough Details

2.26.2 Schering-Plough Major Business

2.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Product and Solutions

2.26.4 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.26.5 Schering-Plough Recent Developments and Future Plans

2.27 Glaxo

2.27.1 Glaxo Details

2.27.2 Glaxo Major Business

2.27.3 Glaxo Targeted Drugs for Multiple Myeloma Product and Solutions

2.27.4 Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.27.5 Glaxo Recent Developments and Future Plans

2.28 Chiron

2.28.1 Chiron Details

2.28.2 Chiron Major Business

2.28.3 Chiron Targeted Drugs for Multiple Myeloma Product and Solutions

2.28.4 Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.28.5 Chiron Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Targeted Drugs for Multiple Myeloma Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Targeted Drugs for Multiple Myeloma Players Market Share in 2021

3.2.2 Top 10 Targeted Drugs for Multiple Myeloma Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Targeted Drugs for Multiple Myeloma Players Head Office, Products and Services Provided

3.4 Targeted Drugs for Multiple Myeloma Mergers & Acquisitions

3.5 Targeted Drugs for Multiple Myeloma New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Targeted Drugs for Multiple Myeloma Revenue and Market Share by Type (2017-2022)

4.2 Global Targeted Drugs for Multiple Myeloma Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2017-2022)

5.2 Global Targeted Drugs for Multiple Myeloma Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2028)

6.2 North America Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2028)

6.3 North America Targeted Drugs for Multiple Myeloma Market Size by Country

6.3.1 North America Targeted Drugs for Multiple Myeloma Revenue by Country (2017-2028)

6.3.2 United States Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

6.3.3 Canada Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

6.3.4 Mexico Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2028)

7.2 Europe Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2028)

7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Country

7.3.1 Europe Targeted Drugs for Multiple Myeloma Revenue by Country (2017-2028)

7.3.2 Germany Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

7.3.3 France Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

7.3.5 Russia Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

7.3.6 Italy Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2028)

8.2 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2028)

8.3 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region

8.3.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Region (2017-2028)

8.3.2 China Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

8.3.3 Japan Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

8.3.4 South Korea Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

8.3.5 India Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

8.3.7 Australia Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2028)

9.2 South America Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2028)

9.3 South America Targeted Drugs for Multiple Myeloma Market Size by Country

9.3.1 South America Targeted Drugs for Multiple Myeloma Revenue by Country (2017-2028)

9.3.2 Brazil Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

9.3.3 Argentina Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2028)

10.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2028)

10.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country

10.3.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue by Country (2017-2028)

10.3.2 Turkey Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

10.3.4 UAE Targeted Drugs for Multiple Myeloma Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Targeted Drugs for Multiple Myeloma Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Targeted Drugs for Multiple Myeloma Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Targeted Drugs for Multiple Myeloma Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Targeted Drugs for Multiple Myeloma Revenue (USD Million) by Region (2017-2022)

Table 5. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Region (2023-2028)

Table 6. Celgene Corporate Information, Head Office, and Major Competitors

Table 7. Celgene Major Business

Table 8. Celgene Targeted Drugs for Multiple Myeloma Product and Solutions

Table 9. Celgene Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Exova Corporate Information, Head Office, and Major Competitors

Table 11. Exova Major Business

Table 12. Exova Targeted Drugs for Multiple Myeloma Product and Solutions

Table 13. Exova Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Natco Pharma Corporate Information, Head Office, and Major Competitors

Table 15. Natco Pharma Major Business

Table 16. Natco Pharma Targeted Drugs for Multiple Myeloma Product and Solutions

Table 17. Natco Pharma Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Intas Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 19. Intas Pharmaceuticals Major Business

Table 20. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product and Solutions

Table 21. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Indiabulls Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 23. Indiabulls Pharmaceutical Major Business

Table 24. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product and Solutions

Table 25. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Cipla Corporate Information, Head Office, and Major Competitors

Table 27. Cipla Major Business

Table 28. Cipla Targeted Drugs for Multiple Myeloma Product and Solutions

Table 29. Cipla Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Glenmark Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 31. Glenmark Pharmaceuticals Major Business

Table 32. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product and Solutions

Table 33. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Dr Reddy's Laboratories Corporate Information, Head Office, and Major Competitors

Table 35. Dr Reddy's Laboratories Major Business

Table 36. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product and Solutions

Table 37. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Qilu Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 39. Qilu Pharmaceutical Major Business

Table 40. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product and Solutions

Table 41. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Chia Tai-Tianqing Corporate Information, Head Office, and Major Competitors

Table 43. Chia Tai-Tianqing Major Business

Table 44. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product and Solutions

Table 45. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Hanson Pharm Corporate Information, Head Office, and Major Competitors

Table 47. Hanson Pharm Major Business

Table 48. Hanson Pharm Targeted Drugs for Multiple Myeloma Product and Solutions

Table 49. Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Meidakang Huakang Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 51. Meidakang Huakang Pharmaceutical Major Business

Table 52. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product and Solutions

Table 53. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Shandong Kongfu Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 55. Shandong Kongfu Pharmaceutical Major Business

Table 56. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product and Solutions

Table 57. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. J&J Corporate Information, Head Office, and Major Competitors

Table 59. J&J Major Business

Table 60. J&J Targeted Drugs for Multiple Myeloma Product and Solutions

Table 61. J&J Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Takeda Corporate Information, Head Office, and Major Competitors

Table 63. Takeda Major Business

Table 64. Takeda Targeted Drugs for Multiple Myeloma Product and Solutions

Table 65. Takeda Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Amgen Corporate Information, Head Office, and Major Competitors

Table 67. Amgen Major Business

Table 68. Amgen Targeted Drugs for Multiple Myeloma Product and Solutions

Table 69. Amgen Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Bristol Myers Squibb Corporate Information, Head Office, and Major Competitors

Table 71. Bristol Myers Squibb Major Business

Table 72. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product and Solutions

Table 73. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Abbvie Corporate Information, Head Office, and Major Competitors

Table 75. Abbvie Major Business

Table 76. Abbvie Targeted Drugs for Multiple Myeloma Product and Solutions

Table 77. Abbvie Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 78. Seattle Genetics Corporate Information, Head Office, and Major Competitors

Table 79. Seattle Genetics Major Business

Table 80. Seattle Genetics Targeted Drugs for Multiple Myeloma Product and Solutions

Table 81. Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 82. Karyopharm Therapeutics Corporate Information, Head Office, and Major Competitors

Table 83. Karyopharm Therapeutics Major Business

Table 84. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product and Solutions

Table 85. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 86. PDL BioPharma Corporate Information, Head Office, and Major Competitors

Table 87. PDL BioPharma Major Business

Table 88. PDL BioPharma Targeted Drugs for Multiple Myeloma Product and Solutions

Table 89. PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 90. Roche Corporate Information, Head Office, and Major Competitors

Table 91. Roche Major Business

Table 92. Roche Targeted Drugs for Multiple Myeloma Product and Solutions

Table 93. Roche Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 94. Sumitomo Corporate Information, Head Office, and Major Competitors

Table 95. Sumitomo Major Business

Table 96. Sumitomo Targeted Drugs for Multiple Myeloma Product and Solutions

Table 97. Sumitomo Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 98. Merck Corporate Information, Head Office, and Major Competitors

Table 99. Merck Major Business

Table 100. Merck Targeted Drugs for Multiple Myeloma Product and Solutions

Table 101. Merck Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 102. Biogen Corporate Information, Head Office, and Major Competitors

Table 103. Biogen Major Business

Table 104. Biogen Targeted Drugs for Multiple Myeloma Product and Solutions

Table 105. Biogen Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 106. Schering-Plough Corporate Information, Head Office, and Major Competitors

Table 107. Schering-Plough Major Business

Table 108. Schering-Plough Targeted Drugs for Multiple Myeloma Product and Solutions

Table 109. Schering-Plough Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 110. Glaxo Corporate Information, Head Office, and Major Competitors

Table 111. Glaxo Major Business

Table 112. Glaxo Targeted Drugs for Multiple Myeloma Product and Solutions

Table 113. Glaxo Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 114. Chiron Corporate Information, Head Office, and Major Competitors

Table 115. Chiron Major Business

Table 116. Chiron Targeted Drugs for Multiple Myeloma Product and Solutions

Table 117. Chiron Targeted Drugs for Multiple Myeloma Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 118. Global Targeted Drugs for Multiple Myeloma Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 119. Global Targeted Drugs for Multiple Myeloma Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 120. Breakdown of Targeted Drugs for Multiple Myeloma by Company Type (Tier 1, Tier 2 and Tier 3)

Table 121. Targeted Drugs for Multiple Myeloma Players Head Office, Products and Services Provided

Table 122. Targeted Drugs for Multiple Myeloma Mergers & Acquisitions in the Past Five Years

Table 123. Targeted Drugs for Multiple Myeloma New Entrants and Expansion Plans

Table 124. Global Targeted Drugs for Multiple Myeloma Revenue (USD Million) by Type (2017-2022)

Table 125. Global Targeted Drugs for Multiple Myeloma Revenue Share by Type (2017-2022)

Table 126. Global Targeted Drugs for Multiple Myeloma Revenue Forecast by Type (2023-2028)

Table 127. Global Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2022)

Table 128. Global Targeted Drugs for Multiple Myeloma Revenue Forecast by Application (2023-2028)

Table 129. North America Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2022) & (USD Million)

Table 130. North America Targeted Drugs for Multiple Myeloma Revenue by Type (2023-2028) & (USD Million)

Table 131. North America Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2022) & (USD Million)

Table 132. North America Targeted Drugs for Multiple Myeloma Revenue by Application (2023-2028) & (USD Million)

Table 133. North America Targeted Drugs for Multiple Myeloma Revenue by Country (2017-2022) & (USD Million)

Table 134. North America Targeted Drugs for Multiple Myeloma Revenue by Country (2023-2028) & (USD Million)

Table 135. Europe Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2022) & (USD Million)

Table 136. Europe Targeted Drugs for Multiple Myeloma Revenue by Type (2023-2028) & (USD Million)

Table 137. Europe Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2022) & (USD Million)

Table 138. Europe Targeted Drugs for Multiple Myeloma Revenue by Application (2023-2028) & (USD Million)

Table 139. Europe Targeted Drugs for Multiple Myeloma Revenue by Country (2017-2022) & (USD Million)

Table 140. Europe Targeted Drugs for Multiple Myeloma Revenue by Country (2023-2028) & (USD Million)

Table 141. Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2022) & (USD Million)

Table 142. Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Type (2023-2028) & (USD Million)

Table 143. Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2022) & (USD Million)

Table 144. Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Application (2023-2028) & (USD Million)

Table 145. Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Region (2017-2022) & (USD Million)

Table 146. Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Region (2023-2028) & (USD Million)

Table 147. South America Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2022) & (USD Million)

Table 148. South America Targeted Drugs for Multiple Myeloma Revenue by Type (2023-2028) & (USD Million)

Table 149. South America Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2022) & (USD Million)

Table 150. South America Targeted Drugs for Multiple Myeloma Revenue by Application (2023-2028) & (USD Million)

Table 151. South America Targeted Drugs for Multiple Myeloma Revenue by Country (2017-2022) & (USD Million)

Table 152. South America Targeted Drugs for Multiple Myeloma Revenue by Country (2023-2028) & (USD Million)

Table 153. Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue by Type (2017-2022) & (USD Million)

Table 154. Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue by Type (2023-2028) & (USD Million)

Table 155. Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue by Application (2017-2022) & (USD Million)

Table 156. Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue by Application (2023-2028) & (USD Million)

Table 157. Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue by Country (2017-2022) & (USD Million)

Table 158. Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Targeted Drugs for Multiple Myeloma Picture

Figure 2. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type in 2021

Figure 3. Immunomodulator

Figure 4. Proteasome Inhibitors

Figure 5. Histone Deacetylase Inhibitors (HDACI)

Figure 6. Monoclonal Antibody

Figure 7. Other

Figure 8. Targeted Drugs for Multiple Myeloma Revenue Market Share by Application in 2021

Figure 9. Hospital Picture

Figure 10. Drug Center Picture

Figure 11. Clinic Picture

Figure 12. Other Picture

Figure 13. Global Targeted Drugs for Multiple Myeloma Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 14. Global Targeted Drugs for Multiple Myeloma Revenue and Forecast (2017-2028) & (USD Million)

Figure 15. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Region (2017-2028)

Figure 16. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Region in 2021

Figure 17. North America Targeted Drugs for Multiple Myeloma Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Europe Targeted Drugs for Multiple Myeloma Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. South America Targeted Drugs for Multiple Myeloma Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. Targeted Drugs for Multiple Myeloma Market Drivers

Figure 23. Targeted Drugs for Multiple Myeloma Market Restraints

Figure 24. Targeted Drugs for Multiple Myeloma Market Trends

Figure 25. Celgene Recent Developments and Future Plans

Figure 26. Exova Recent Developments and Future Plans

Figure 27. Natco Pharma Recent Developments and Future Plans

Figure 28. Intas Pharmaceuticals Recent Developments and Future Plans

Figure 29. Indiabulls Pharmaceutical Recent Developments and Future Plans

Figure 30. Cipla Recent Developments and Future Plans

Figure 31. Glenmark Pharmaceuticals Recent Developments and Future Plans

Figure 32. Dr Reddy's Laboratories Recent Developments and Future Plans

Figure 33. Qilu Pharmaceutical Recent Developments and Future Plans

Figure 34. Chia Tai-Tianqing Recent Developments and Future Plans

Figure 35. Hanson Pharm Recent Developments and Future Plans

Figure 36. Meidakang Huakang Pharmaceutical Recent Developments and Future Plans

Figure 37. Shandong Kongfu Pharmaceutical Recent Developments and Future Plans

Figure 38. J&J Recent Developments and Future Plans

Figure 39. Takeda Recent Developments and Future Plans

Figure 40. Amgen Recent Developments and Future Plans

Figure 41. Bristol Myers Squibb Recent Developments and Future Plans

Figure 42. Abbvie Recent Developments and Future Plans

Figure 43. Seattle Genetics Recent Developments and Future Plans

Figure 44. Karyopharm Therapeutics Recent Developments and Future Plans

Figure 45. PDL BioPharma Recent Developments and Future Plans

Figure 46. Roche Recent Developments and Future Plans

Figure 47. Sumitomo Recent Developments and Future Plans

Figure 48. Merck Recent Developments and Future Plans

Figure 49. Biogen Recent Developments and Future Plans

Figure 50. Schering-Plough Recent Developments and Future Plans

Figure 51. Glaxo Recent Developments and Future Plans

Figure 52. Chiron Recent Developments and Future Plans

Figure 53. Global Targeted Drugs for Multiple Myeloma Revenue Share by Players in 2021

Figure 54. Targeted Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 55. Global Top 3 Players Targeted Drugs for Multiple Myeloma Revenue Market Share in 2021

Figure 56. Global Top 10 Players Targeted Drugs for Multiple Myeloma Revenue Market Share in 2021

Figure 57. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 58. Global Targeted Drugs for Multiple Myeloma Revenue Share by Type in 2021

Figure 59. Global Targeted Drugs for Multiple Myeloma Market Share Forecast by Type (2023-2028)

Figure 60. Global Targeted Drugs for Multiple Myeloma Revenue Share by Application in 2021

Figure 61. Global Targeted Drugs for Multiple Myeloma Market Share Forecast by Application (2023-2028)

Figure 62. North America Targeted Drugs for Multiple Myeloma Sales Market Share by Type (2017-2028)

Figure 63. North America Targeted Drugs for Multiple Myeloma Sales Market Share by Application (2017-2028)

Figure 64. North America Targeted Drugs for Multiple Myeloma Revenue Market Share by Country (2017-2028)

Figure 65. United States Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Canada Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Mexico Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Europe Targeted Drugs for Multiple Myeloma Sales Market Share by Type (2017-2028)

Figure 69. Europe Targeted Drugs for Multiple Myeloma Sales Market Share by Application (2017-2028)

Figure 70. Europe Targeted Drugs for Multiple Myeloma Revenue Market Share by Country (2017-2028)

Figure 71. Germany Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. France Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. United Kingdom Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Russia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Italy Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Asia-Pacific Targeted Drugs for Multiple Myeloma Sales Market Share by Type (2017-2028)

Figure 77. Asia-Pacific Targeted Drugs for Multiple Myeloma Sales Market Share by Application (2017-2028)

Figure 78. Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue Market Share by Region (2017-2028)

Figure 79. China Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Japan Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. South Korea Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. India Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 83. Southeast Asia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 84. Australia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 85. South America Targeted Drugs for Multiple Myeloma Sales Market Share by Type (2017-2028)

Figure 86. South America Targeted Drugs for Multiple Myeloma Sales Market Share by Application (2017-2028)

Figure 87. South America Targeted Drugs for Multiple Myeloma Revenue Market Share by Country (2017-2028)

Figure 88. Brazil Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 89. Argentina Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 90. Middle East and Africa Targeted Drugs for Multiple Myeloma Sales Market Share by Type (2017-2028)

Figure 91. Middle East and Africa Targeted Drugs for Multiple Myeloma Sales Market Share by Application (2017-2028)

Figure 92. Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue Market Share by Country (2017-2028)

Figure 93. Turkey Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 94. Saudi Arabia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 95. UAE Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 96. Methodology

Figure 97. Research Process and Data Source